Hitachi Systems India Pvt. Ltd. and Cyemptive Technologies Inc. Announce Agreement to Jointly Provide Cyemptive’s Award-Winning Cybersecurity Solutions to Hitachi Systems IT Customers
Hitachi Systems India Pvt. Ltd. ("Hitachi Systems India"), a wholly owned subsidiary of Hitachi Systems (TSE: 6501), today announced their agreement with Cyemptive Technologies, Inc., an award-winning provider of preemptive cybersecurity solutions for business and government, to jointly provide Cyemptive Technology’s next-generation cybersecurity innovations, including on-demand, end-to-end secure platform solutions, to Hitachi Systems India’s Southeast Asia/Middle East and India customers.
Under the terms of the agreement, Hitachi Systems India will provide Cyemptive’s cybersecurity solutions to its IT customers, starting with the India, Southeast Asia, and Middle East markets. As a group company of Hitachi Systems, one of the leading providers of IT services and cybersecurity worldwide, Hitachi Systems India provides comprehensive one-stop IT business services, ranging from cybersecurity offerings, system design, construction, operations, and maintenance. According to Hitachi Systems India, the purpose of this strategic agreement is to provide a comprehensive solution to the ever-growing financial and reputational cybersecurity risk for its customers.
“Cyemptive’s award-winning solutions are moving cyber-defense to an entirely new level, and we are excited to launch this strategic agreement that, combined with Hitachi Systems India’s capabilities, will actually provide the answer that truly cyber-protects our customers,” said Anuj Gupta, CEO of Hitachi Systems India.
Cyemptive has created the next generation of cybersecurity that is essential for businesses to achieve cyber safety. Cyemptive’s cybersecurity solutions preclude damage from occurring even from previously unknown attack techniques, and are the only ones on the market today that protect computing environments before or immediately following a compromise.
“Hitachi Systems India shares over a one-hundred-year legacy of technology innovation from Hitachi Limited throughout the world. Cyemptive is proud to combine our unique solutions with the outstanding IT services and experience from Hitachi,” said Rob Pike, founder and CEO of Cyemptive Technologies. “Together, we will effectively address the ever-growing financial and reputational cybersecurity risk for Hitachi Systems India customers.”
About Cyemptive Technologies
Headquartered in Seattle, Wash., Cyemptive has been on a mission to make large organizations cyber safe since 2014. Today, Cyemptive’s award-winning software, services and support are used by businesses and government entities worldwide. It is the winner of the 2019 Department of Homeland Security’s Border Security Technology Consortium (BSTC) competition for most innovative border security-related solution in the market, as well as 10 ‘ASTORS’ Homeland Security Awards from American Security Today at the 2022 competition alone - more than any other company in the history of the awards. The company’s leadership team is comprised of executives from several of the world’s most powerful technology and security organizations, including the former CIO of Microsoft and the former Chief Computer Architect for the National Security Agency. More information about Cyemptive Technologies is available at www.cyemptive.com.
About Hitachi Systems India Pvt. Ltd.
Hitachi Systems India Pvt. Ltd. is an IT services company that was founded in New Delhi in 1991 and became a group company of Hitachi Systems in 2014. Utilizing their vast experience in the Indian market, their advanced technological expertise, and the comprehensive strength of Hitachi, the global technology leader, they are capable of delivering the expertise required to manage a range of digital ecosystems from cables to the cloud. They believe that every single organization has its own unique DNA. While continuing to promote the unified corporate vision of Social Innovation, they help each and every customer retain their sense of uniqueness through the provision of customized and flexible engagement and operating models that result in IT services and solutions that are tailored to individual businesses. With their extensive pool of more than 2,000 experienced employees, they operate 10 offices and more than 200 service bases throughout India. For more details, please refer to https://hitachi-systems.co.in.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231114960817/en/
Contact information
Belinda Young
BYPR
206-932-3145
byoung@bypr.com
Rob Pike
Cyemptive Technologies
425-341-9800
info@cyemptive.com
Lynn McLean
SVP of Sales
Cyemptive Technologies, Inc.
415-515-4691
lmclean@cyemptive.com
Vivek Gupta
Hitachi Systems India Private Limited
Senior VP
9871690901
vivek.gupta.ac@hitachi-systems.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom